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Cannabinoids	 have	 been	 shown	 to	 exert	 a	 neuroprotective	 influence	 in	 organophosphorus-
induced	toxicity.	In	our	study,	we	examined	the	effects	of	 the	cannabinoid	receptor	agonist	
WIN55,212-2	and	NMDA	receptor	agonist	NMDA	on	cell	death	 in	 the	pheochromocytoma	
cell	line	PC12	subjected	to	the	action	of	an	organophosphorus	compound,	diazinon.	Diazinon	
decreased	 cell	 viability	 in	 a	 concentration-dependent	 manner.	 Following	 the	 exposure	 of	
PC12	 cells	 to	 	 200	 µM	 diazinon	 for	 48	 h,	 reductions	 in	 cell	 survival	 and	 protein	 level	 of	
CB1	 receptors	 were	 observed.	 Treatment	 of	 the	 cells	 with	 0.1	 µM	WIN55,212-2	 and	 100	
µM	NMDA	 	 prior	 to	 diazinon	 exposure	 significantly	 elevated	 the	 cell	 survival	 level	 	 and	
protein	level	of	CB1	receptors.	The	cannabinoid	antagonist	AM251	(1	µM)	did	not	inhibit	the	
neuroprotection	effect	induced	by	WIN55,212-2,	indicating	that	the	neuroprotective	effect	of	
this	agonist	was	cannabinoid	receptor-independent.	The	NMDA	receptor	antagonist	MK-801	
(1	µM)	enhanced	diazinon-mediated	neurotoxicity	suggesting	that	precisely	NMDA	receptors	
may	play	a	protective	role.	
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INTRODUCTION 
Diazinon	 (O,O-diethyl-O-[2-isopropyl-6-methyl-4-
pyrimidinyl]	phosphorothioate)	is	an	organophosphorus	
(OP)	 agent	widely	 used	 as	 a	 pesticide.	Diazinon	 can	
enter	the	organism	through	inhalation,	ingestion,	and/
or	 skin	 contact.	 This	 OP	 is	 a	 hydrophobic	 molecule	
and,	 therefore,	 can	 easily	 penetrate	 biological	
membranes,	 especially	 via	 phospholipid	 bilayers	
[1].	 Different	 studies	 showed	 that	 diazinon	 inhibits	
acetylcholinesterase	 (AChE)	 activity	 and	 protein	
synthesis	 in	 PC12	 cells	 [2].	 In	 other	 studies,	 it	 was	
reported	that	this	compound	disturbs	DNA	synthesis	in	
and	induces	apoptosis	of	PC12	cells	[3,	4].	Sublethal	
concentrations	 of	 diazinon	 inhibit	 the	 outgrowth	 of	
axon-like	 processes	 from	 differentiating	 mouse	 N2a	
neuroblastoma	and	PC12	cells	[4,	5].	
Cannabinoids	are	a	group	of	C
21
	compounds	occur-
ring	 in	 the	 glandular	 hairs	 of	Cannabis sativa.	 The	
well-known	 representative	 cannabinoid	 is	 ∆9-tetra-
hydrocannabinol	 (∆9-THC)	 [6].	The	endocannabinoid	
system	 includes	specific	cannabinoid	 receptors	 (CB1	
and	CB2),	 their	 endogenous	 ligands,	 and	 enzymatic	
systems	of	their	biosynthesis	and	degradation	[7].	Syn-
thetic	and	endogenous	cannabinoids	were	shown	to	ex-
ert,	under	certain	conditions,	neuroprotective	effects	
in	animals	and	in vitro	models	with	respect	to	various	
forms	of	neuronal	 injury,	 such	as	 cerebral	 ischemia,	
traumatic	brain	injury,	toxicity,	and	neurodegenerative	
disorders	[8,	9].	In vitro	and	in vivo	experiments	dem-
onstrated	that	neuroprotective	effects	of	cannabinoids	
are	probably	not	mediated	via	CB1	receptors	[10,	11].	
It	 is	well	 established	 that	NMDA	and	endogenous	
cannabinoids	 display	 complex	 interactions	 in	 their	
control	of	synaptic	plasticity	 [12].	 In	particular,	CB1	
receptors	are	located	presynaptically	on	glutamatergic	
projections	 to	 the	hippocampus.	Thus,	CB1	receptors	
and	 glutamate	 receptors	 are	 expressed	 on	 the	 same	
neuronal	 elements.	 These	 two	 receptor	 types	 were	
found	 to	 display	 a	 complex	 signaling	 interaction	 in	
primary	hippocampal	neuron	cultures	[13].	
PC12	 cells	 (a	 neuronal	 model	 cell	 line)	 are	
widely	used	as	an	 in vitro	model	 in	 investigations	of	
development,	pathogenesis,	 and	 toxicity.	PC12	cells	
were	 shown	 to	 express	 cannabinoid	 CB1	 receptors	
NEUROPHYSIOLOGY	/	НЕЙРОФИЗИОЛОГИЯ.—2013.—T.	45,	№	6530
F.	BAHRAMI,	M.	HASHEMI,	F.	KHALILI	et	al.
[14],	 although	 some	 reports	 suggest	 that	 the	 cells	
are	 not	 endowed	with	 this	 receptor	 type	 [15].	 PC12	
cells	 also	 seem	 to	 be	 a	 suitable	 system	 for	 studying	
important	features	of	NMDA	receptors	[16].	
In	 our	 study,	 a	 toxicity	model	with	 diazinon	 as	 a	
toxic	 agent	was	 examined	under	 in vitro	 conditions.	
Then,	the	neuroprotective	effects	of	the	CB1	receptor	
agonist	 WIN55,212-2	 and	 NMDA	 receptor	 agonist	
NMDA	 were	 assessed	 against	 diazinon-induced	
toxicity	 in	 PC12	 cells.	 Also,	 the	 CB1	 receptor	
antagonist	 AM251	 and	 NMDA	 receptor	 antagonist	
MK801	 were	 used	 in	 our	 study.	 Finally,	 possible	
interactions	 between	 CB1	 receptors	 and	 ionotropic	
glutamate	 receptors,	 including	 those	 of	 the	 NMDA	
type,	were	examined	in	PC12	cells	under	conditions	of	
diazinon-induced	toxicity.	To	date,	there	are	no	studies	
of	interactions	between	these	two	receptor	types.	
METHODS
Materials. The PC12	 cell	 line	 was	 purchased	
from	 the	Pasteur	 Institute	 (Tehran,	 Iran).	Dulbecco’s	
modified	 Eagle’s	 medium	 (DMEM)/F12	 and	 fetal	
bovine	 serums	 (FBS)	 were	 obtained	 from	 Gibco	
Life	Technologies	 (USA).	The	CellTitre	96	AQueous	
One	 Solution	 Cell	 Proliferation	 Assay	 Kit	 was	
from	 Promega	 Corporation	 (USA).	 WIN55,212-2,	
AM251	 and	 N-methyl-	 D-aspartate	 (NMDA)	 were	
purchased	 from	 Tocris	 (Great	 Britain);	 MK801,	
diazinon,	 Triton	 X-100,	 and	 other	 chemicals	 were	
from	 Sigma-Aldrich	 (USA).	 Rabbit	 polyclonal	
ant ibody	 directed	 toward	 the	 CB1	 receptor	 
(Sc-20754)	 and	 goat	 anti-rabbit 	 IgG	 antibody	
conjugated	 with	 horseradish	 peroxidase	 (Sc-2004)	
were	from	Santa	Cruz	Biotechnology	(USA).
Cell Culturing. PC12	 cells	 were	 grown	 in	 the	
DMEM	supplemented	with	10%	FBS	+	100	units/ml	 
antibiotic/antimycotic. 	 These	 cells 	 were	 then	
incubated	in	a	humidified	chamber	containing	5%	CO
2
 
at	37ºC.	For	the	experiments,	confluent	cultures	were	
harvested	with	trypsin	and	then	re-suspended	in	5	ml	
of	 the	medium	supplemented	with	FBS	(to	 inactivate	
trypsin).	The	cells	were	seeded	into	6	well	or	96	well	
plates	 and	 allowed	 to	 adhere	 for	24	h	 at	 37ºC	 in	 air	
with	5%	CO
2
.
Drug Exposure. Our	treatment	samples	included	the	
following	 groups:	 (i)	 PC12	 cells	 treated	with	 200	 µM	 
diazinon,	 0.1	 µM	 cannabinoid	 receptor	 agonist	
WIN55,212-2,	100	µM	NMDA	receptor	agonist	NMDA	
and	 1	 µM	 MK801	 in	 the	 separate	 groups	 for	 48	 h.	
Pretreatment	of	PC12	cells	with	different	drugs	took	place	
15	min	before	exposure	to	diazinon.	Diazinon	itself	was	
in	the	well	for	48	h.	(ii)	PC12	cells	pretreated	with	0.1	µM	 
WIN55,212-2	 and	 then	 exposed	 to	 200	 µM	 diazinon.	
(iii)	 PC12	 cells	 pretreated	with	 a	 cannabinoid	 receptor	
antagonist	 AM251	 (1	 µM);	 then,	 WIN55,212-2	 and	
diazinon	were	added	after	another	15-min-long	interval		for	 
48	 h	 (AM+WIN+DZ).	 (iv)	 In	 another	 group,	
PC12	 cells	 were	 pretreated	 with	 100	 µM	 NMDA	
before	 being	 exposed	 to	 200	 µM	 diazinon	 for	 48	 h	
(NMDA+DZ).	 (v)	 PC12	 cells	 were	 pretreated	 with	 
1	 µM	MK801;	 then,	NMDA	was	 added;	 15	min	 later,	
diazinon	 was	 introduced	 for	 48	 h	 (MK+NMDA+DZ).	
(vi)	 In	 this	 group,	 drugs	 were	 added,	 respectively,	 in	
the	 group	 of	 WIN55,212-2,	 NMDA,	 and	 diazinon	 at	
15-min-long	 intervals	 (WIN+NMDA+DZ).	 (vii)	 In	 this	
group,	 WIN55,212-2,	 NMDA,	 MK801,	 and	 diazinon	
were	 also	 added,	 respectively,	 at	 15-min-long	 intervals	
(WIN+NMDA+MK+DZ).	 (viii)	 In	 the	 final	 group,	
WIN55,212-2,	 MK801,	 NMDA,	 and	 diazinon	 were	
added	 in	 the	 order	 mentioned	 above	 also	 at	 15-min-
long	 intervals	 (WIN+MK+NMDA+DZ).	 All	 drugs	
(WIN55,212-2,	AM251,	NMDA,	MK801,	and	diazinon)	
were	dissolved	in	dimethyl	sulfoxide	(DMSO)	and	diluted	
in	 the	 culturing	 medium	 to	 the	 desired	 concentration.	
The	final	concentration	of	DMSO	was	less	than	0.1%,	a	
concentration	that	exerted	no	confounding	effects	on	the	
responses	under	study.	
Measurement of Cell Viability.	 Cell	 viability	
was	measured	 using	 the	 CellTitre	 96	AQueous	One	
Solution	 (MTS)	 Cell	 Proliferation	Assay	 Kit.	 Cells	
(104	 per	 well	 in	 200	 µl	 medium)	 were	 seeded	 in	 
96	well	plates	and	allowed	to	adhere	for	24	h	at	37ºC.	
The	medium	was	 replaced	with	a	 fresh	medium,	and	
cells	were	exposed	to	the	medium	containing	200	µM	
diazinon	or	 cannabinoid	 and	 to	NMDA	agonists	 and	
antagonists	with	and	without	diazinon	(incubation	for	
48	 h	 at	 37°C).	 The	 treatment	media	were	 removed,	
and	 the	 cells	 were	 washed	 with	 phosphate	 buffer	
saline	 (PBS).	Then,	100	µl	of	 the	serum-free	culture	
medium	 containing	 20	µl	 of	CellTitre	 96®	AQueous	
One	 Solution	 Reagent	 [3-(4,5-dimethylthiazol- 
2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sulfophenyl)-	
2H-tetrazolium]	MTS	was	added	into	each	well	of	the	
96-well	assay	plate	and	re-incubated	 for	2	h	at	37ºC.	
The	absorbance	of	the	sample	was	recorded	at	490	nm	
using	a	Wallac	microplate	reader.	The	MTS	reduction	
values	 were	 expressed	 as	 percentage	 of	 the	 control	
(untreated	cells).	
Cell Lysis and Protein Assay. 	 PC12	 cells	 were	
plated	 in	 6-well	 culture	 plates	 at	 the	 density	 of	 
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106	 cells/well.	After	48-h-long	 treatment,	 cells	were	
lysed	 by	 the	 following	 procedure.	The	medium	was	
removed,	and	cells	were	washed	twice	with	cold	PBS.	
Cells	were	then	lysed	in	500	µl	of	the	lysis	buffer	(Tris-
HCl,	50	mM;	NaCl,	500	mM;	EDTA,	5	mM,	and	Triton	
X-100,	0.2%	v/v	(pH	7.5)	supplemented	with	protease	
inhibitors.	 The	 cell	 lysate	 was	 sonicated	 for	 1	 min	
on	 ice.	Then,	 the	 lysate	was	centrifuged	at	10,000	g	 
at	4ºC	 for	15	min.	The	supernatant	was	 removed	 for	
protein	assay.	The	protein	concentration	was	measured	
using	bovine	serum	albumin	as	a	standard	[17].
Analysis of CB1 Receptor Protein by Western 
Blotting. The	 resulting	 supernatants	 were	 used	 for	
quantitative	 analysis	 of	 the	 CB1	 receptor	 amount	
by	 Western	 Blotting.	 Each	 sample	 containing	 
20	µg	protein	was	separated	by	SDS–polyacrylamide	
gel	 electrophoresis	 (PAGE)	 on	 a	 12%	 gel.	 After	
electrophoresis,	 the	 protein	 was	 transferred	 to	 a	
nitrocellulose	membrane	 (20	V).	Blots	were	blocked	
with	5%	fat-free	milk	in	Tris-buffered	saline	containing	
0.05%	Tween	20	(TBS-T)	for	1	h	at	room	temperature.	
The	 nitrocellulose	 membrane	 was	 incubated	 with	 1	
to	200	dilutions	of	 rabbit	polyclonal	CB1R	antibody	 
(sc-20754,	 Santa	 Cruz,	 USA)	 in	 5%	 fat-free	 milk	
TBS-T	for	overnight	at	4ºC.	After	washing	with	TBS-T,	
the	nitrocellulose	membrane	was	incubated	with	HRP-
conjugated	anti-rabbit	 IgG	(1	 to	10,000	dilution)	 for	
60	 min.	 Finally,	 the	 nitrocellulose	 membrane	 was	
incubated	 with	 the	 3,3′,5,5′	 tetramethybenzidine	
(TMB)	 liquid	 substrate	 system	 until	 protein	 bands	
appeared.	
Statistical Analysis. In	 the	Western	 Blot,	 protein	
bands	 were	 quantified	 using	 densitometry	 by	 NIH	
Imager	 software	 and	 normalized	 with	 respect	 to	 the	
β-actin	 band	 intensity.	 Protein	 bands	were	 expressed	
as	percentages	of	the	control	level.	Numerical	data	are	
presented	below	as	means	±	 s.e.m.	Statistical	 testing	
used	 one-way	 analysis	 of	 variance	 followed	 by	 the	
Tukey’s	test.	The	criterion	for	statistical	significance	of	
differences	was	P	<	0.05	for	all	comparisons.
RESULTS 
Cytotoxicity and Cell Viability of PC12 Cells at 
Different Concentrations of Diazinon. To	determine	
whether	 diazinon	 is	 neurotoxic,	 its	 effect	 on	 the	
viability	 of	 cultured	 PC12	 cells	 was	 examined	 (Fig.	
1).	 Survival	 of	 the	 cells	was	 presented	 as	 a	 function	
of	 the	 diazinon	 concentration	 after	 treatment,	
using	 the	 MTS	 assay	 as	 a	 measure	 of	 cell	 viability.	
Exposure	 of	 PC12	 cells	 to	 100	 to	 400	 µM	 diazinon	
reduced	 cell	 viability	 in	 a	 dose-dependent	 manner.	
Concentrations	 of	 300	 and	 400	 µM	 were	 toxic	 to	
the	 cells,	 and	 the	 rate	 of	 cell	 death	 increased.	 At	
200	 µM	 diazinon,	 cell	 survival	 was	 reduced	 to	 20%	
of	 the	 untreated	 cells	 (control)	 and	 was,	 therefore,	
used	 for	 subsequent	 experiments	 on	 toxic	 effects	 
(a	concentration	that	produced	a	submaximal	effect	on	
cell	 viability)	 (Fig.	 1,	 P	 <	 0.05,	 one-way	ANOVA).	
In	the	previous	study,	different	doses	of	WIN55,212-2	 
(0.1-100	 µM)	 were	 assayed.	 WIN55,212-2	 exerted	
a	 neurotoxic	 effect	 at	 a	 1	 µM	 dose	 and	 higher	 with	
respect	 to	 the	 control.	 WIN55,212-2	 at	 a	 0.1	 µM	
concentration	 was	 not	 toxic;	 this	 concentration	
was,	 therefore,	 deemed	 appropriate	 for	 subsequent	
experiments	 on	 neuroprotective	 effects	 in	 PC12	
cells	 [10].	 In	 addition,	 the	 protective	 effect	 of	 
0.1	µM	WIN55,212-2	was	examined	in	the	presence	of	
different	 doses	 of	 diazinon.	Any	 dose	 increase	 could	
decrease	 the	 protective	 ability	 of	 WIN55,212-2	 at	 
0.1	µM	(Fig.	1,	P	<	0.05,	one-way	ANOVA).
Protective Effects of WIN55,212-2 Applied 
Different Times Prior to Diazinon. The effects of 
WIN55,212-2	were	 examined	 in	 cases	where	 it	was	
applied	 at	 different	 time	 intervals	 prior	 to	 induction	
of	 toxicity.	 Co-treatment	 of	 WIN55,212-2	 with	
diazinon	was	not	effective.	WIN55,212-2	application	
for	 15	 min	 prior	 to	 diazinon	 provided	 better	 cell	
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F i g. 1.	Toxic	effects	of	different	concentrations	of	diazinon	and	
the	 protective	 influence	 of	 0.1	 mM	 WIN55,212-2	 	 on	 cultured	
pheochromocytoma	 PC12	 cells.	 Concentrations	 of	 diazinon,	µM,	
are	shown	below	the	columns;	Contr.	is	the	control.	Vertical	scale)	
Index	of	viability	of	PC12	cells,	%;	that	in	the	control	is	taken	as	
100%.	Gray	 columns,	 viability	 in	 the	presence	of	 diazinon;	filled	
columns,	 that	 in	 the	presence	of	both	diazinon	and	WIN55,212-2.	
**	and	***	indicate	significant	intergroup	differences	vs	control	with	
P	 <	 0.01	 and	P	 <	 0.001,	 respectively;	 +	 and	 ++	 symbols	 indicate	
cases	with	P <	0.05	and	0.01	in	comparison	with	the	diazinon	group.	
ANOVA	+	Tukey;	n	=	6	in	all	cases.
Р и с. 1. 	 Токсичні	 ефекти	 діазинону	 в	 різних	 концентраціях	
та	протективний	вплив	0.1	мкМ	WIN55,212-2	на	культивовані	
клітини	феохромоцитоми	PC12.
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survival	 compared	 to	 the	 effect	 of	 diazinon	 alone.	
At	 the	 same	 time,	 adding	WIN55,212-2	 24	 h	 before	
diazinon	 significantly	 reduced	 the	 protective	 effect	
with	respect	 to	diazinon.	Therefore,	all	pretreatments	
with	WIN55,212-2	were	 set	 to	 happen	 15	min	 prior	
to	 diazinon	 application	 (Fig.	 2,	P	 <	 0.05,	 one-way	
ANOVA).		
WIN55,212-2 and Survival of PC12 Cells. 
Incubation	 of	 PC12	 cells	with	 200	µM	diazinon	 for	
48	 h	 induced	 cell	 death	 up	 to	 20%	 (P	 <	 0.01).	Cell	
survival	in	the	group	treated	with	WIN55,212-2	alone	
was	 greater.	 The	 addition	 to	 0.1	 µM	WIN55,212-2	 
significantly	increased	PC12	cell	survival	(P	<	0.01).	
To	 determine	 whether	 the	 neuroprotective	 effect	
of	 WIN55,212-2	 was	 CB1	 receptor-mediated,	 the	
above	 receptors	 were	 blocked	 	 with	 its	 antagonist	
AM251.	The	cells	were	treated	with	1	µM	AM251	for	 
15	min	prior	to	incubation	with	0.1	µM	WIN55,212-2.	 
Under	 such	conditions,	 the	neuroprotective	effect	of	
WIN55,212-2	 was	 not	 abolished	 (Fig.	 3,	P	 <	 0.05,	
one-way	ANOVA).		
Protective Effect of NMDA on Diazinon-Induced 
Toxicity. The	 treatment	with	 1	 µM	NMDA	 receptor	
antagonist	MK801	alone	for	48	h	somewhat	worsened	
cell	survival,	though	insignificantly.	At	the	same	time,	
cell	 survival	 in	 the	 group	 treated	 with	 the	 NMDA	
receptor	 agonist	 (NMDA	 alone)	 for	 48	 h	 increased	
the	viability	vs	unexposed	control	cells	(insignificant	
increase).	Diazinon	(200	µM)	alone	killed	20%	of	the	
cells.	 Pretreatment	 with	 NMDA	 not	 only	 prevented	
the	 reduction	of	 the	cell	number	 induced	by	200	µM	
diazinon,	 but	 it	 raised	 the	 viability	 by	 about	 25%	 
(P	<	0.01).	To	determine	whether	the	viability	increase	
due	to	NMDA	was	mediated	by	receptors	to	the	latter,	
the	 cells	 were	 pretreated	 with	 the	 NMDA	 receptor	
antagonist	MK-801	followed	by	the	addition	of	NMDA	
and	diazinon	for	48	h.	In	this	group	(MK+NMDA+DZ),	
MK-801,	 due	 to	 blocking	 of	 NMDA	 receptors,	
increased	the	neurotoxicity	of	diazinon	by	about	15%.	
(Fig.	4,	P	<	0.05,	one-way	ANOVA).
WIN55,212-2 and NMDA Interaction with Respect 
to the Diazinon-Induced Toxicity. When	WIN55,212-
2	and	NMDA	were	used	 in	combination,	 two	groups	
(WIN+NMDA+DZ	 and	 WIN+NMDA+MK801+DZ)	
revealed	 neuroprotective	 effects	 (P	 <	 0.05).	 At	
the	 same	 time,	 cell	 survival	 in	 the	WIN55,212-2	 +	
MK801+	+	NMDA	+	diazinon	group	was	significantly	
lower	 (P	<	0.05).	We	hypothesized	 that	NMDA	may	
help	WIN55,212-2	 to	protect	 cells	 against	 diazinon-
mediated	 neurotoxicity.	 Therefore,	 we	 pretreated	
cultured	cells	with	1	µM	MK801	for	15	min	prior	 to	
F i g. 2.	 Protective	 effect	 of	 0.1	 µM	 WIN55,212-2	 against	 
200	mM	diazinon	(DZ)-induced	toxicity,	dependence	on	time	prior	
to	the	diazinon	exposure	(shown	below	the	columns).	Cell	viability	
was	assessed	48	h	after	the	beginning	of	incubation	with	diazinon.	
Other	designations	are	similar	to	those	in	Fig.	1.
Р и с. 2.	 Протективний	 вплив	 0.1	 мкM	 WIN55,212-2	 в	 разі	
нейротоксичного	 ефекту,	 індукованого	 200	 мкM	 діазинону:	
залежність	від	інтервалу	часу	перед	експозицією	до	діазинону.
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F i g. 3.	 Effect	 of	 0.1	 µM	WIN55,212-2	 and	 1	 µM	AM251	 on	 
200	 µM	 diazinon-induced	 cell	 death.	 Cell	 viability	 was	
assessed	 48	 h	 after	 the	 beginning	 of	 incubation	 with	 diazinon;	 
WIN55,212-2	 and	 AM251	 were	 added	 15	 min	 before	 diazinon.	
Agents	added	to	the	culture	medium	are	shown	below	the	columns.	
Other	designations	are	similar	to	those	in	Figs.	1	and	2.	
Р и с. 3.	 Впливи	 0.1	 мкM	WIN55,212-2	 та	 1	 мкM	AM251	 на	
клітинну	загибель,	індуковану	200	мкM	діазинону.
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F i g. 4.	Effects	of	 a	glutamate	 receptor	 agonist	 (NMDA)	and	an	
antagonist	 (MK-801)	 on	 diazinon-induced	 neurotoxicity.	 PC12	
cells	 were	 treated	 with	 200	 µM	 diazinon	 (DZ),	 NMDA,	 and	
DZ	 added	 15	 min	 after	 NMDA	 in	 the	 presence	 or	 absence	 of	 
MK-801.	Other	designations	are	similar	to	those	in	Figs.	1-3.	
Р и с. 4.	 Впливи	 агоніста	 глутаматних	 рецепторів	 NMDA	 та	
антагоніста	цих	рецепторів	MK-801	на	нейротоксичні	ефекти,	
індуковані	діазиноном.
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or	15	min	after	the	addition	of	NMDA.	The	protective	
effect	of	NMDA	was	completely	blocked	by	MK-801	
in	 this	 group	 (WIN+MK801+NMDA+DZ).	 It	 seems	
that	 NMDA	 can	 help	WIN55,212-2	 to	 protect	 cells	
when	 there	was	no	MK801	or	NMDA	was	not	added	
before	MK801.	Thus,	 the	 toxic	effect	 in	 the	group	of	
WIN+MK801+NMDA+DZ	 is	 significantly	 greater	
than	that	in	the		diazinon	group	(Fig.	5,	P	<	0.05,	one-
way	ANOVA).
Levels of CB1 Receptor Protein in PC12 
Cells Treated with Diazinon. The	 levels	 of	 CB1	
receptor	 protein	 in	 unexposed	 control	 and	diazinon-
exposed	 PC12	 cells	 were	 assayed	 by	Western	 Blot	
analysis	 employing	 polyclonal	 anti-CB1	 receptor	
antibody.	 Protein	 bands	 with	 a	 molecular	 mass	 of	
45-60	 kDa	 were	 observed.	 Compared	 to	 that	 in	
unexposed	 cells,	 the	 level	 of	 CB1	 receptor	 protein	
decreased	 significantly	 in	 the	 cells	 exposed	 to	 
200	 µM	 diazinon	 (P	 <	 0.001).	 The	 CB1	 receptor	
agonist	 alone	 (at	 a	 concentration	 used	 in	 this	
experiment)	exerted	no	significant	effect	on	 the	CB1	
receptor	protein	 level	 in	PC12	cells.	 	 In	 the	presence	
and	 absence	 of	AM251,	 the	 level	 of	 CB1	 receptor	
protein	 was	 significantly	 higher	 as	 compared	 with	
that	in	the	diazinon	alone	group	(P	<	0.01).	Similarly	
to	 viability	 experiments,	 AM251	 did	 not	 prevent	
the	 increase	 of	CB1	 expression	 in	 the	 cells	 (Fig.	 6,	 
P	<	0.05,	one-way	ANOVA).
Levels of CB1 Receptor Protein at Interaction 
of NMDA and WIN55,212-2. It	 was	 supposed	 that	
NMDA	 would	 increase	 CB1	 receptor	 expression	
when	applied	in	association	with	WIN55,212-2	in	the	
absence	of	MK801	or	in	the	case	where	the	latter	was	
applied	 before.	 In	 agreement	 with	 this	 supposition,	
it	 was	 found	 that	 NMDA	 can	 help	WIN55,212-2	 in	
CB1	 receptor	 expression	 (WIN+NMDA+DZ	 and	
WIN+NMDA+MK+DZ).	 However,	 inhibition	 of	
NMDA	 receptors	 with	 MK801	 application	 prior	 to	
NMDA	 decreased	 CB1	 receptor	 expression	 (Fig.	 7,	 
P	<	0.05,	one-way	ANOVA).
DISCUSSION
In	 our	 study,	 several	 concentrations	 of	 diazinon	
were	 used	 to	 determine	 effective	 amounts	 of	 the	
latter.	 Diazinon	 induced	 concentration-dependent	
decreases	 in	 cell	 viability.	 Diazinon	 in	 the	 
200	 µM	 dose	 decreased	 cell	 survival	 and	 CB1	
receptor	 expression	 after	 48	 h-long	 exposure.	 In	
our	 earlier	 works	 with	 OPs,	 we	 found	 that	 sublethal	
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F i g. 5.	 Interaction	 between	WIN55,212-2,	 an	 NMDA	 receptor	
agonist,	 and	 an	NMDA	 receptor	 antagonist	 in	 the	 effects	 against	
diazinon-induced	 neurotoxicity.	 PC12	 cells	 were	 treated	 by	 the	
shown	 agents	 15	 min	 prior	 to	 diazinon.	 Other	 designations	 are	
similar	to	those	in	Figs.	1-4.		
Р и с. 5.	 Взаємодія	WIN55,212-2,	 агоніста	NMDA-рецепторів	
та	 антагоніста	 цих	 рецепторів	 в	 їх	 впливах	 на	 нейротоксичні	
ефекти	діазинону.
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F i g. 6.	 Assay	 of	 CB1	 receptor	 expression	 in	 PC12	 cells.	 The	
effect	 of	 cannabinoids	 on	 the	 levels	 of	 CB1	 receptors	 in	 PC12	
cells	 exposed	 to	 a	 sublethal	 concentration	 of	 diazinon	 (200	µM).	
Solubilized	 PC12	 cellular	 extracts	 were	 subjected	 to	 SDS-PAGE	
(20	µg	protein	per	 lane),	 blotted	 to	nitrocellulose	membrane,	 and	
incubated	 with	 rabbit	 antibody	 (Sc-20754)	 directed	 specifically	
against	 CB1	 receptors	 and	 followed	 with	 HRP-conjugated	 goat	
anti-rabbit	 IgG	 (Sc-2004).	 A)	 Results	 of	 blotting;	 B)	 table	 of	
the	 agents	 acting	 on	 the	 samples	 whose	 analysis	 is	 shown	 in	A,	 
and	C)	mean	densitometric	indices	of	the	band	for	CB1	(45-60	kDa)	
normalized	with	respect	to	the	β-actin	band	intensity	and	expressed	
as	percentage	of	 the	control	 level.	Number	of	repetitions	n	=	3	 in	
all	cases.	Designations	on	panel	C	are	similar	to	those	in	Figs.	1-5.	
Р и с. 6.	Експресії	рецепторів	CB1	у	клітинах	PC12.
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concentrations	 of	 diazinon	 inhibited	 the	 outgrowth	
of	 axon-like	 processes	 and	 induced	 apoptosis	 of	
differentiated	 PC12	 cells	 [4,	 18].	 Other	 researchers	
also	 reported	 that	 diazoxon	 inhibited	AChE	 activity	
and	 reduced	 transcripts	 of	 the	 α4	 and	 β2	 subunits	 of	
nAChRs	 (at	 the	 mRNA	 level)	 in	 PC12	 cells	 [2].	 In	
addition,	expression	of	serotonergic	neuronal	markers	
was	detracted	in	PC12	cells	[19].
In	 this	 study,	 we	 hypothesized	 that	WIN55,212-
2	 may	 protect	 PC12	 cells	 against	 toxicity,	 and	 we	
checked	 this	hypothesis	under	 in vitro	 conditions	on	
PC12	cells.	It	was	found	that	WIN55,212-2	increases	
cell	 survival	 and	 CB1	 receptor	 expression.	 So,	 the	
protective	 effect	 is	 obvious.	 According	 to	 earlier	
studies,	 WIN55,212-2	 demonstrated	 a	 protective	
effect	against	 toxic	 insults	 induced	by	glutamatergic	
overstimulation	 [20],	 β-amyloid	 [21],	 hypoxic/
ischemic	 injury	 [22],	 and	 oxidative	 damage	 [23].	
The	molecular	mechanisms	 of	 such	 neuroprotective	
effect	 are	 still	 controversial	 but	 might	 involve	
direct	activation	of	pro-survival	 signalling	pathways	
including	 cannabinoid	 receptors	 (mainly	CB1)	 [24].	
In	 general,	 the	 protective	 effect	 of	 cannabinoids	 is	
dependent	 on	 special	 conditions	 (such	 as	 adequate	
doses	 and	 short	 exposure	 times)	 and	may	be	 related	
to	 the	 enhancement	 of	 proliferation	 [25].	 However,	
high	 doses	 of	 these	 agents	 and	 long	 exposure	 times	
inhibit	 cell	 growth	 and/or	 induce	 apoptosis	 via	
activation	 of	 caspases	 3	 and	 7	 [26].	 Consistent	
with	 these	 studies,	 it	 was	 reported	 that	 the	 CB1	
receptor	 agonist	WIN55,212-2	 protected	 PC12	 cells	
from	 diazinon-induced	 neurotoxicity	 in	 a	 low	 dose	 
(0.1	µM)	and	with	a	short	exposure	time	(15	min).
Moreover,	it	was	shown	that	WIN55,212-2	provided	
neuroprotection	is	not	mediated	via	direct	cannabinoid	
receptor	 activation.	 This	 finding	 was	 confirmed	
using	 the	 CB1	 receptor	 antagonist	AM251.	AM251	
did	 not	 decrease	 the	 viability	 and	 CB1	 receptor	
expression	 increased	by	WIN55,212-2	 in	PC12	cells.	
However,	in	our	previous	work	where	PC12	cells	were	
differentiated	under	the	action	of	neural	growth	factor	
(NGF),	AM251	inhibited	the	neuroprotective	effect	of	
WIN55,212-2	[4].	Hence,	the	reason	for	this	disparity	
seems	to	be	related	to	the	cell	differentiation	process.	
Molderings	 et	 al.	 [15]	 reported	 that	undifferentiated	
PC12	 cells	 do	 not	 express	 detectable	 amounts	
of	 CB1	 receptors.	 Since	 the	 level	 of	 activity	 is	
generally	 related	 to	 the	 number	 of	 active	 receptors,	
the	 antagonism	 is	 usually	 more	 considerable	 under	
conditions	of	elevated	receptor	expression	[27].
A	 few	mechanisms	have	been	proposed	 to	explain	
the	CB1-independent	 neuromodulatory	 effect.	 First,	
cannabinoids	 can	 alter	 the	 membrane	 fluidity	 and	
other	 physiochemical	 properties	 of	 the	 membrane.	
Second,	cannabinoids	directly	modulate	the	functional	
properties	of	voltage-	and	 ligand-gated	 ion	channels	
in	 the	 membrane	 [28].	 Our	 experiments	 showed	
that	 activation	 of	 NMDA	 receptors	 by	 a	 subtoxic	
concentration	 of	 NMDA	 (100	 µM)	 in	 the	 culture	
medium	 is	 selectively	 involved	 in	 the	 protection	
of	 the	 cells	 against	 diazinon,	 whereas	 the	 NMDA	
receptor	 antagonist	 MK-801	 increases	 diazinon-
mediated	neurotoxicity.	 It	 seems	 that	MK801	blocks	
NMDA	receptors	and	 interferes	with	NMDA-induced	
protection.	 Consistent	 with	 these	 results,	 other	
investigators	 reported	 that	NMDA	(100	µM)	protects	
cerebellar	 granular	 cells	 from	 paraoxon-induced	
toxicity.	 This	 study	 suggests	 that	 NMDA	 (100	 µM)	
completely	blocks	caspase-3	activation	responsible	for	
inducing	apoptosis	and	protects	almost	all	vulnerable	
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F i g. 7. Assay	 of	 CB1	 receptor	 expression	 in	 PC12	 cells.	
Interaction	 between	 WIN55,212-2,	 an	 NMDA	 agonist,	 and	 an	
NMDA	 antagonist	 in	 the	 effects	 on	 the	 levels	 of	 CB1	 receptors	
in	 PC12	 cells	 exposed	 to	 a	 sublethal	 concentration	 of	 diazinon	 
(200	 µM).	 Procedures	 of	 analysis	 are	 similar	 to	 those	 in	 Fig.	 6;	
panels	A-C	are	similar	to	those	in	this	Figure.	Designations	in	panel	
C	are	similar	to	those	in	Figs.	1-6.
Р и с. 7.	Експресія	рецепторів	CB1	у	клітинах	PC12.
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neurons	 against	 paraoxon-induced	 neuronal	 cell	
death	 [29].	 Furthermore,	 a	 few	 researches	 reported	
that	 NMDA-mediated	 neuroprotection	 is	 provided	
by	 distinct	 mechanisms.	 Among	 them,	 there	 are	 a	
calcium-dependent	mechanism	[30],	 inhibition	of	 the	
pro-apoptotic	 JNK	 pathway	 [31],	 activation	 of	 pro-
survival	pathways	(MAPK/ERK1/2,	PI3-K/Akt,	PKA/
CREB,	and	NF
κ
B)	[32],	and	regulation	of	transcription	
of	 the	antioxidant	 system	[33].	Activation	of	NMDA	
receptors	 is	 vitally	 important	 for	 development	 and	
survival	of	CNS	neurons	in	the	developing	brain;	this	
factor	 enhances	 differentiation	 and	 survival	 of	 the	
neurons	[34].
A	 controversial	 situation	 related	 to	 receptor	
interactions	 deserves	 attention.	 We	 tried	 to	 reveal	
possible	 interactions	 between	 CB1	 and	 NMDA	
receptors.	Our	findings	showed	for	 the	first	 time	that	
NMDA	helps	WIN55,212-2	 to	 increase	 	cell	 survival	
and	to	enhance	CB1	receptor	expression;	it	should	be	
taken	 into	 account	 that	 these	 two	 receptor	 types	 are	
integrated	 together	 in	PC12	cells.	Furthermore,	other	
studies	demonstrated	that	mGlu1α	and	CB1	receptors	
are	 co-expressed	 in	 a	 subpopulation	 of	 interneurons	
in	 the	CA1	 stratum radiatum	 of	 hippocampal	 slices	
(double	 immunofluorescence	 staining	 and	 confocal	
microscopy	were	used).	It	seems	that	mGlu1α	and	CB1	
receptors	expressed	on	the	same	CA1	interneurons	may	
play	a	cooperative	 role	 in	 the	 regulation	of	 synaptic	
signalling	in	CA1	pyramidal	cells	[13].	Other	studies	
suggested	 that	 there	 are	 strong	 direct	 and	 indirect	
interactions	between	cannabinoid	CB1	receptors	and	
group	 II	metabotropic	glutamate	 receptors	 signaling	
in	 layer-V	 pyramidal	 neurons	 in	 the	 rat	 prefrontal	 
cortex	[12].	
Therefore,	diazinon	 is	a	strong	 toxicant	capable	of	
damaging	PC12	cells.	Diazinon	reduces	cell	viability	
and	 inhibits	 expression	 of	 CB1	 receptors	 in	 these	
cells.	 WIN55,212-2	 and	 NMDA	 noticeably	 protect	
PC12	 cells	 against	 diazinon	 toxicity.	The	 protective	
effect	 of	WIN55,212-2	 seems	 to	 be	 CB1	 receptor-
independent	 (considering	 the	 presence	 of	 action	 of	
AM251).	 However,	 MK801	 inhibits	 the	 protective	
effect	of	NMDA.	As	a	result,	we	should	conclude	that	
NMDA	exerts	its	protective	action	precisely	via	these	
receptors.	 Finally,	 it	 is	 possible	 that	WIN55,212-2	 
and	 NMDA	 actively	 interact	 in	 mediation	 of	 their	
protective	effects.	
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Р	е	з	ю	м	е
Було	показано,	що	канабіноїди	забезпечують	нейропротек-
тивний	 вплив	 у	 разі	 токсичності,	 індукованої	 фосфорор-
ганічними	 сполуками.	Ми	 досліджували	 впливи	 агоніста	
канабіноїдних	рецепторів	WIN55.212-2	та	агоніста	NMDA-
рецепторів	на	загибель	культивованих	клітин	феохромоци-
томи	PC12,	 зумовлену	дією	фосфорорганічної	сполуки	ді-
азинону.	Діазинон	 зменшував	життєздатність	 цих	 клітин,	
і	 його	 вплив	 був	 	 дозозалежним.	Після	 експозиції	 клітин	
PC12	 до	 200	 мкM	 діазинону	 спостерігалася	 посилена	 за-
гибель	 даних	 клітин	 при	 зменшенні	 рівня	 білка	 рецепто-
рів	CB1.	Дія	на	клітини	0.1	мкM	WIN55,212-2	та	100	мкM	
NMDA,	що	 передувала	 їх	 експозиції	 до	 діазинону,	 істот-
но	підвищувала	рівень	виживання	клітин	та	рівень	протеї-
ну	згаданих	рецепторів.	Антагоніст	канабіноїдів	AM251	(1	
мкM)	не	пригнічував	нейропротективної	дії	WIN55,212-2,	
що	свідчило	про	незалежність	впливу	даного	агоніста	від	
дії	 безпосередньо	 на	 канабіноїдні	 рецептори.	Антагоніст	
NMDA-рецепторів	MK-801	 (1	мкM)	посилював	 індуковані	
діазиноном	нейротоксичні	впливи.	Це	вказувало	на	те,	що	
саме	NMDA-рецептори,	вірогідно,	відіграють	протективну	
роль	в	аналізованій	ситуації.
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